Literature DB >> 10071464

Life-threatening bleeding in a case of autoantibody-induced factor VII deficiency.

K Okajima1, M Ishii.   

Abstract

A male patient presented with life-threatening bleeding induced by autoantibody-induced factor VII (F.VII) deficiency. This patient had macroscopic hematuria, skin ecchymosis, gastrointestinal bleeding, and a neck hematoma that was causing disturbed respiration. He developed acute renal failure and acute hepatic failure, probably due to obstruction of the ureters and the biliary tract, respectively. Although activated partial thromboplastin time was normal, prothrombin time (PT) was remarkably prolonged at 71.8 seconds compared to 14.0 seconds in a normal control. Both the immunoreactive level of F.VII antigen and the F.VII activity of the patient's plasma samples were < 1.0% of normal. Although an equal part of normal plasma was added to the patient's plasma, PT was not corrected. The patient's plasma inhibited F.VII activity. These findings suggested the presence of a plasma inhibitor for F.VII. After administration of large doses of methylprednisolone, PT was gradually shortened and plasma levels of F.VII increased over time. Bleeding, acute renal failure, and acute hepatic failure improved markedly following the steroid treatment. These observations suggest that life-threatening bleeding can be induced by autoantibody-induced F.VII deficiency and that immunosuppressive therapy using large doses of steroid can be successful in inhibiting the production of the autoantibody.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10071464

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  3 in total

1.  Acquired factor VII deficiency following FOLFOX in a patient with colorectal cancer who was also DPD deficient.

Authors:  Muhammad Wasif Saif; Komal Wasif; Harriette Butler-Bowen; Kenneth Miller; Robert B Diasio
Journal:  Therap Adv Gastroenterol       Date:  2016-01       Impact factor: 4.409

2.  Development of a transgenic mouse model with immune tolerance for human coagulation factor VIIa.

Authors:  Christine Lenk; Sabine Unterthurner; Maria Schuster; Markus Weiller; Gerhard Antoine; Mantas Malisauskas; Friedrich Scheiflinger; Hans-Peter Schwarz; Maurus de la Rosa; Birgit M Reipert
Journal:  Pharm Res       Date:  2013-06-18       Impact factor: 4.200

3.  A Neonate with Acquired Factor VII Deficiency Successfully Managed with Immunomodulatory Therapy.

Authors:  Nof Saadi Alqarni; Ali H Algiraigri
Journal:  Int J Pediatr Adolesc Med       Date:  2020-12-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.